{"id":390618,"date":"2018-07-31T00:00:00","date_gmt":"2018-07-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0003-2018-biopharma-rheumatoid-arthritis-current-treatment-eu5-2018\/"},"modified":"2026-05-04T23:25:04","modified_gmt":"2026-05-04T23:25:04","slug":"cutrim0003-2018-biopharma-rheumatoid-arthritis-current-treatment-eu5-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0003-2018-biopharma-rheumatoid-arthritis-current-treatment-eu5-2018\/","title":{"rendered":"Rheumatoid Arthritis | Current Treatment | EU5 | 2018"},"content":{"rendered":"<p>Five TNF\u00a0inhibitors, five\u00a0biologics with alternative mechanisms of action, and two JAK inhibitors\u00a0are approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy, Spain, and the United Kingdom). The TNF\u00a0inhibitors are the most widely prescribed biologics in RA patients refractory to conventional DMARDs owing to their efficacy, postmarketing safety data, and physicians\u2019 familiarity with them. However, the high-priced, branded TNF\u00a0inhibitors face a competitive threat from the launch of biosimilars, including biosimilar infliximab, biosimilar etanercept, and biosimilar\u00a0rituximab, which provide cost-effective alternatives. In addition, the newlylaunched oral JAK\u00a0inhibitors are poised to take market share away from biological injections. The <em>Rheumatoid Arthritis Current Treatment (EU5)<\/em> content provides in-depth analysis of rheumatologists\u2019 treatment and prescribing practices in the crowded RA market, including drivers of treatment selection, obstacles to biologics use, analysis of patient share, and anticipated changes in drug usage.<\/p>\n","protected":false},"template":"","class_list":["post-390618","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-product-current-treatment","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390618\/revisions"}],"predecessor-version":[{"id":393742,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390618\/revisions\/393742"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}